Company profile
Abattis Bioceuticals Corp.
OTC: ATTBF · Healthcare · Medical - Pharmaceuticals
Canadian filerHQ Vancouver, BCReports USD
#978 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ —GM —SS 40
v0.1 · 5/100 weight · pillars only
↑ revenue growth (YoY), return on assets · ↓ disclosure history, market scale
Methodology →Revenue TTM
$269.0k
Rev growth YoY (TTM)
+4005.8%
Net income (FY)
-$2.3M
Employees
48
as of 2026-08-29
Market cap
$14.3k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$268.9k356.9k CAD2019
Net income-$2.3M-3.0M CAD2019
Operating income-$3.0M-4.0M CAD2019
Total assets$14.5M19.3M CAD2019
Liabilities$6.5M8.6M CAD2019
Equity$8.4M11.1M CAD2019
Revenue trend
FY2017 – FY2019 · USD
FY17
FY18
FY19
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Abattis Bioceuticals Corp.’s revenue?
Abattis Bioceuticals Corp. booked $268.9k in FY2019 revenue, growing 4024% year over year — faster than 98% of Healthcare companies we track, at a -852.4% net margin.
Peers · Healthcare
CannAmerica Brands Corp.——Hydrogen Hybrid Technologies, Inc.——Aion Therapeutic Inc.——Entia Biosciences, Inc.——CEL-SCI Corporation32DNutra Pharma Corp.30DKey facts
CEORobert G. Goodall
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersVancouver, BC
ExchangeOTC: ATTBF
Employees48
IPO date2014-05-29
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.